Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia
Status:
Completed
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
This is a 24-week, randomized, double-blind, placebo-controlled trial of exenatide weekly
injection (2mg per dose) as an adjunctive therapy in 70 schizophrenia subjects to examine
exenatide's effects on negative symptoms and cognition.